Respiratory syncytial virus vaccine
Trade names Arexvy, Abrysvo
Routes of administration Intramuscular
RSV vaccine protects against infection by respiratory syncytial virus.
The RSV vaccines are Arexvy and Abrysvo
Abrysvo is approved for use in pregnant individuals to prevent lower respiratory tract disease and severe lower respiratory tract disease caused by respiratory syncytial virus in infants from birth through six months of age.
Respiratory syncytial virus vaccine is indicated for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in people 60 years of age and older.
RSV affects an estimated 64 million people and causes 160,000 deaths worldwide each year.
Vaccine development obstacles: infant-specific factors, such as the immature infant immune system and the presence of maternal antibodies, which make infantile immunization difficult.
RSV fusion (F) protein provides the basis for finding the most effective F protein constructs used in RSV vaccines.
One dose of the vaccine provided 94% efficacy against severe RSV pneumonia and 72% efficacy against RSV acute respiratory infection.
In a study, approximately 12,500 participants received respiratory syncytial virus vaccine, adjuvanted and 12,500 participants have received a placebo: the vaccine significantly reduced the risk of developing RSV-associated lower respiratory tract disease by 82.6% and reduced the risk of developing severe RSV-associated lower respiratory tract disease by 94.1%.
RSVpreF (Abrysvo) is a bivalent recombinant protein subunit vaccine which consists of equal amounts of stabilized prefusion F antigens from the two major RSV subgroups: RSV A and RSV B.
An mRNA – 1345 RSV vaccine encoding the stabilized RSV prefusion F glycoprotein.
I’m a phase III study of a RSV vaccine for adults age 60 and above in over 34,000 participants: One dose of the vaccine provided 67% efficacy in preventing infections with at least two symptoms.
The vaccine was 86% effective against more severe disease, in people with three related symptoms.
The vaccine’s protection was was 62% effective in preventing acute respiratory illness caused by RSV infection.
In a double blind phase III study of a respiratory syncytial virus vaccine in about 3,600 pregnant women, with 3,600 women receiving a placebo.
One dose of the vaccine provided 81% efficacy in preventing severe infection in the infant within three months after birth and 69% in six months after birth.
This vaccine is recommended this vaccine for approval in pregnant women to prevent lower respiratory tract disease and severe lower respiratory tract disease caused by respiratory syncytial virus in infants from birth through six months of age.
It is approved for use at 32 through 36 weeks gestational age of pregnancy.
The most commonly reported side effects by pregnant individuals who received Abrysvo were pain at the injection site, headache, muscle pain and nausea.
Among approximately 3,500 pregnant individuals who received Abrysvo, compared to approximately 3,500 pregnant individuals who received placebo:
Abrysvo reduced the risk of severe lower respiratory tract disease by 81.8% within 90 days after birth, and 69.4% within 180 days after birth.
In a subgroup of pregnant individuals who were 32 through 36 weeks gestational age, of whom approximately 1,500 received Abrysvo and 1,500 received placebo, Abrysvo reduced the risk of lower respiratory tract disease by 34.7%, and reduced the risk of severe lower respiratory tract disease by 91.1% within 90 days after birth when compared to placebo.
Within 180 days after birth, Abrysvo reduced the risk of lower respiratory tract disease by 57.3% and by 76.5% for severe lower respiratory tract disease, when compared to placebo.